A Study of PVX-410, a Cancer Vaccine, and Citarinostat +/- Lenalidomide for Smoldering MM (clinicaltrials.gov) - Oct 8, 2026 - P1 | N=19 | Active, not recruiting | Sponsor: Massachusetts General Hospital | Trial completion date: Sep 2026 ➔ Feb 2027 | Trial primary completion date: Sep 2026 ➔ Feb 2027
Trial completion date • Trial primary completion date • Hematological Malignancies • Multiple Myeloma • Oncology • Smoldering Multiple Myeloma
|